RESUMO
Forty-six heroin abusers were hospitalized and treated with meperidine either alone or in association with clonidine. Meperidine was given orally in rapidly decreasing doses according to three different schedules. The majority of patients (87%) successfully completed the detoxification program. The best meperidine starting posology was 200 mg four times daily, which allowed stoppage of the opioid treatment after gradual reduction of the daily dose in a mean time of 9.5 days. Association with clonidine was not proven to be useful. This study shows that meperidine can be effectively used in rapidly decreasing doses in the pharmacological detoxification treatment of hospitalized heroin addicts.
Assuntos
Dependência de Heroína/reabilitação , Hospitalização , Meperidina/administração & dosagem , Administração Oral , Adolescente , Adulto , Terapia Combinada , Relação Dose-Resposta a Droga , Esquema de Medicação , Feminino , Seguimentos , Dependência de Heroína/psicologia , Humanos , Masculino , Pessoa de Meia-Idade , Pacientes Desistentes do Tratamento/psicologia , Abuso de Substâncias por Via Intravenosa/reabilitaçãoRESUMO
The prevalence of HTLV III/LAV antibody has been studied in six groups of population: healthy subjects, a virological laboratory staff, prisoners, drug addicts, patients with lymphoadenopathy-associated syndrome (LAS) and patients with AIDS. Prevalences and levels in the same groups of HBsAg and CMV, HSV 1 and HSV 2 antibodies have been studied, too. As expected, the prevalence of HTLV III/LAV antibody increases in the six groups with the increasing of the risk while the prevalences of the other markers of viral infection do not show such a pattern. The levels of positivity of CMV antibody are significantly higher in the prisoners and LAS groups versus healthy subjects suggesting a possible role of this virus in the developing of full-blown AIDS.
